You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞製藥-B(09966.HK)治療實體瘤藥物澳洲臨床研究顯示患者耐受良好
阿思達克 11-16 12:31
康寧傑瑞製藥-B(09966.HK)公布,有關JSKN003在澳洲進行的治療HER2表達晚期實體瘤的I期臨床研究的初步結果,公司已在JSKN003-101中觀察到JSKN003的初步療效和良好的耐受性。 JSKN003在HER2表達的實體瘤中已初顯療效,接受治療的患者耐受良好,未發生過劑量限制性毒性反應,未達到最大耐受劑量(MTD)。目前正在中國進行JSKN003的I/II期臨床試驗,截止10月26日已入組56例受試者,其安全性資料與JSKN003-101一致,未識別出新的安全性信號。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account